by admin | Jul 3, 2026 | Q-Research Grants
Targeted radionuclide therapy delivers ionizing radiation to tumor cells through the accumulation of intravenously injected radiopharmaceuticals. In the case of metastatic castration-resistant prostate cancer, the currently used agent [177Lu]Lu-PSMA-617 is limited by...
by admin | Jun 30, 2026 | Q-BOARD OF TRUSTE
Trustee of ICPO Foundation and Chairman of Portland Holdings Limited, Canada
by admin | Jun 30, 2026 | Q-BOARD OF TRUSTE
Trustee of ICPO Foundation and Founder of ITM Isotope Technologies Munich SE Germany
by admin | Jun 30, 2026 | Q-BOARD OF TRUSTE
President of ICPO Academy for Theranostics, Chairman of the Scientific Advisory Board of the ICPO Foundation and Nuclear Medicine Physician at Curanosticum Wiesbaden Germany
by admin | Jun 26, 2026 | Q-NEWS
With the aspiration of treating 1 million patients worldwide with high standards of care, ICPO is building a strong network of ICPO Clinical Theranostics Centers of Excellence, which reached over 50 centers in 2025. The foundation offers a structured accreditation...
